Moderna reshapes leadership and ops model as it pushes into oncology, rare disease

CEO Stéphane Bancel framed the changes as essential to scaling the business

Moderna posts Q1 2026 loss despite revenue surge

Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets

Moderna teams up with Recordati to commercialize rare disease therapy

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year